A phase i study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin

BJU International

Volumn 108, Issue 6, 2011, Pages 831-838

  Matsumoto, Kazumasa ^a   Noguchi, Masanori ^b   Satoh, Takefumi ^a   Tabata, Ken Ichi ^a   Fujita, Tetsuo ^a   Iwamura, Masatsugu ^a   Yamada, Akira ^b   Komatsu, Nobukazu ^b   Baba, Shiro ^a   Itoh, Kyogo ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

bladder cancer; peptide vaccine; personalized therapy; phase I clinical trial; urothelial carcinoma

Indexed keywords

CANCER VACCINE; CISPLATIN; CYPB 129 PEPTIDE VACCINE; DOXORUBICIN; EZH2 735 PEPTIDE VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HNRPL 140 PEPTIDE VACCINE; HNRPL 501 PEPTIDE VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LCK 422 PEPTIDE VACCINE; LCK 486 PEPTIDE VACCINE; LCK 488 PEPTIDE VACCINE; MAP 432 PEPTIDE VACCINE; METHOTREXATE; MRP3 1293 PEPTIDE VACCINE; PAP 213 PEPTIDE VACCINE; PEPTIDE VACCINE; PERSONALIZED PEPTIDE VACCINE; PSA 248 PEPTIDE VACCINE; PTHRP 102 PEPTIDE VACCINE; SART3 109 PEPTIDE VACCINE; UBE2V 43 PEPTIDE VACCINE; UBE2V 85 PEPTIDE VACCINE; UNCLASSIFIED DRUG; VINBLASTINE; WHSC2 103 PEPTIDE VACCINE; WHSC2 141 PEPTIDE VACCINE;

ADULT; ADVANCED CANCER; AGED; ANTIBODY TITER; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; BONE METASTASIS; CLINICAL ARTICLE; CYSTECTOMY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; INJECTION SITE REDNESS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHROURETERECTOMY; OPEN STUDY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT DURATION; URINARY TRACT CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INDIVIDUALIZED MEDICINE; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOMOGRAPHY, X-RAY COMPUTED; UROLOGIC NEOPLASMS; VACCINES, SUBUNIT; VINBLASTINE;

EID: 80052087754     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09933.x     Document Type: Article

References (30)

1. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-7 (Pubitemid 15129797)
2. Saxman SB, Propert KJ, Einhorn LH, et al,. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9 (Pubitemid 27289886)
3. von der Maase H, Hansen SW, Roberts JT, et al,. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77
4. von der Maase H, Sengelov L, Roberts JT, et al,. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8 (Pubitemid 46224062)
5. Novellino L, Castelli C, Parmiani G,. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187-207 (Pubitemid 40174238)
6. Rosenberg SA,. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7 (Pubitemid 29165283)
7. Sharma P, Shen Y, Wen S, et al,. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sc USA 2007; 104: 3967-72 (Pubitemid 47181562)
8. Sharma P, Gnjatic S, Jungbluth AA, et al,. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003; 3: 19
9. Sharma P, Bajorin DF, Jungbluth AA, et al,. Immune responses detected in urethelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31: 849-57
10. Siefker-Radtke A,. Bladder cancer: can we move beyond chemotherapy? Curr Oncol Rep 2010; 12: 278-83
11. Mine T, Sato Y, Noguchi M, et al,. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10: 929-37 (Pubitemid 38198892)
12. Tsuda N, Mochizuki K, Harada M, et al,. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 60-72 (Pubitemid 38076169)
13. Noguchi M, Itoh K, Yao A, et al,. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63: 1-12 (Pubitemid 40365385)
14. Yajima N, Yamanaka R, Mine T, et al,. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11: 5900-11 (Pubitemid 41170319)
15. Noguchi M, Kakuma T, Uemura H, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 1001-9
16. Finke LH, Wentworth K, Blumenstein B, et al,. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; B97-B109 (Pubitemid 47488554)
17. Goldman B, DeFrancesco L,. The cancer vaccine roller coaster. Nat Biotechnol 2009; 27: 129-39
18. Sasada T, Komatsu N, Suekane S, et al,. Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46: 1514-9
19. Yanagimoto H, Mine T, Yamamoto K, et al,. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007; 98: 605-11 (Pubitemid 46562753)
20. Aucouturier J, Dupuis L, Ganne V,. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19: 2666-72 (Pubitemid 32234287)
21. Hida N, Maeda Y, Katagiri K, et al,. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002; 51: 219-28 (Pubitemid 34493956)
22. Noguchi M, Mine T, Yamada A, et al,. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 2007; 16: 341-9 (Pubitemid 47488078)
23. Komatsu N, Shichijo S, Nakagawa M, Itoh K,. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64: 535-45 (Pubitemid 39318358)
24. Noguchi M, Yao A, Harada M, et al,. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007; 67: 933-42 (Pubitemid 46828927)
25. Valmori D, Souleimanian NE, Tosello V, et al,. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007; 104: 8947-52 (Pubitemid 47175417)
26. + T cells reactive to a class I tumor peptide. J Immunol 2004; 172: 2659-67 (Pubitemid 38182418)
27. Matsumoto K, Irie A, Satoh T, et al,. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol 2007; 14: 1000-4; discussion 4 (Pubitemid 47621839)
28. Uhm JE, Lim HY, Kim WS, et al,. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 2007; 9: 18-22
29. Han KS, Joung JY, Kim TS, et al,. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 2008; 98: 86-90
30. Clement LT,. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. J Clin Immunol 1992; 12: 1-10